Biogen Idec, Genentech release study results for rheumatoid arthritis treatment

SOUTH SAN FRANCISCO, Calif. An investigational treatment for rheumatoid arthritis was successful in improving the signs and symptoms of rheumatoid arthritis, according to results of a late-stage clinical trial released Friday.

Biogen Idec and Roche subsidiary Genentech announced results of a phase 3 study of ocrelizumab combined with methotrexate in patients who had not responded adequately to methotrexate alone.

“Patients living with a debilitating disease like rheumatoid arthritis can benefit from additional treatment options,” Biogen Idec VP and chief medical officer for rheumatology David Hagerty said. “We look forward to seeing the results of our ongoing phase 3 rheumatoid arthritis trials with ocrelizumab.”

The two companies expect to have results of three other trials of the drug in the first half of 2010.